News

DENVER – The International Association for the Study of Lung Cancer (IASLC) applauds the U.S. FDA’s decision to extend its regulation of tobacco products to e-cigarettes, cigars, hookah tobacco, and pipe tobacco, among other products. This action by the FDA puts these products more in alignment with the Family Smoking Prevention and Tobacco Control Act and is a vast step forward for public health.

DENVER –A pre-competitive consortia of pharmaceutical, diagnostic companies and academic associations, including the International Association for the Study of Lung Cancer (IASLC), announced phase I results of the “BLUEPRINT PD-L1 IHC ASSAY COMPARISON PROJECT” at the Annual Meeting of the American Association for Cancer Research (AACR) on April 19. The study compared four PD-L1 IHC diagnostic assays developed in conjunction with four PD-1/PD-L1 immune checkpoint inhibitors, which are used in NSCLC clinical trials.

May 2016 Newsletter

This year’s European regional meeting, the European Lung Cancer Conference (ELCC), recently concluded in Geneva, Switzerland.

DENVER – Capturing and summarizing the remarkable progress in lung cancer prevention, diagnosis, staging, and treatment in 2015, the International Association for the Study of Lung Cancer (IASLC) announces the inaugural publication of “Scientific Advances in Lung Cancer 2015” in the May 2016 issue of the IASLC’s Journal of Thoracic Oncology (JTO).

DENVER – This month, the International Association for the Study of Lung Cancer (IASLC) launched a global newsmagazine, the IASLC Lung Cancer News, to disseminate the latest developments in prevention, treatment and care of patients with thoracic malignancies to academia, the oncology community and the general public.

GENEVA, Switzerland, 15 April 2016 – The benefit of plasma genotyping to predict treatment benefit in patients with non-small-cell lung cancer (NSCLC) is confirmed in three studies presented today at the European Lung Cancer Conference (ELCC) 2016 in Geneva, Switzerland.1 Researchers however warned that plasma tests are unlikely to fully replace tissue biopsies.

Pages